Search results for " prognostic factor"

showing 8 items of 28 documents

Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a …

2014

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable re…

OncologyMaleNon–muscle-invasive bladderBacillus Calmette-Guerin; BCG; Non-muscle-invasive bladder cancer; Prognostic factors; T1G3Settore MED/24 - UrologiaRisk groupsRetrospective StudieRisk FactorsBCGAge Factorskin and connective tissue diseasesBacillus Calmette-GuerinBacillus (shape)Prognostic factorbiologyBacillus Calmette-Gue´rin BCG Non–muscle-invasive bladder cancer Prognostic factors T1G3Age FactorsBacillus Calmette-Gue´rinMiddle AgedPrognosisTumor BurdenBacilluSurvival RateUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Urinary Bladder NeoplasmBCG VaccineDisease ProgressionFemaleNon muscle invasiveCalmette-GuérinCarcinoma in SituHumanmedicine.medical_specialtyPrognosiNon-muscle-invasive bladder cancerUrologyUrologyT1G3Prognostic factorsCystectomyRisk AssessmentNon–muscle-invasive bladder cancerFollow-Up StudieAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicinecancerHumansAgedRetrospective StudiesBladder cancerbusiness.industryRisk Factorbiology.organism_classificationmedicine.diseaseMulticenter studyUrinary Bladder NeoplasmsProper treatmentNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean urology
researchProduct

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergr…

2022

Abstract Background: The management of melanoma patients with metastatic sentinel nodes (SN) is evolving based on the results of trials questioning the impact of completion lymph node dissection (CLND) and demonstrating the efficacy of new adjuvant treatments. In this landscape, new prognostic tools for fine risk stratification are eagerly sought to optimize the therapeutic path of these patients. Methods: A retrospective cohort of 2,086 patients treated with CLND after a positive SN biopsy in thirteen Italian Melanoma Centers was reviewed. Overall survival (OS) was the outcome of interest; included independent variables were the following: age, gender, primary melanoma site, Breslow thickn…

OncologyMaleTreatment of cutaneous melanomamedicine.medical_specialtyCompletion lymph node dissectionSkin NeoplasmsCLND; Completion lymph node dissection; Melanoma; Metastatic melanoma in the sentinel nodes; Nomogram; Overall survival; Prognostic factors; Risk stratification; Treatment of cutaneous melanoma; Tumor burden; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Prognosis; Retrospective Studies; Sentinel Lymph Node Biopsy; Tumor Burden; Lymphadenopathy; Melanoma; Sentinel Lymph Node; Skin NeoplasmsTumor burdenSettore MED/19 - Chirurgia PlasticaLymphadenopathyPrognostic factorsNomogramInternal medicineBiopsymedicineMetastatic melanoma in the sentinel nodesHumansCLNDOverall survivalMelanomaCLND; Completion lymph node dissection; Melanoma; Metastatic melanoma in the sentinel nodes; Nomogram; Overall survival; Prognostic factors; Risk stratification; Treatment of cutaneous melanoma; Tumor burdenRisk stratificationRetrospective Studiesmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyMelanomaTumor burdenSentinel nodemedicine.diseasePrognosisLymphatic MetastasisLymph Node ExcisionSentinel Lymph Nodebusiness
researchProduct

What is the prognostic importance of lymphovascular space invasion in the absence of lymph node metastasis for early-stage endometrial cancer?

2021

Objective: The aim of this study is to analyze the prognostic role of lymph-vascular space invasion (LVSI), evaluated in a semi-quantitative fashion on prognosis of early stage, low risk endometrial cancer (EC). Methods: We enrolled patients who underwent surgery for endometrial cancer between 2003 and 2018 in two referral cancer center. All patients had endometrioid EC, G1–G2, with myometrial invasion <50%, and no lymph-node involvement. LVSI was analyzed in a semi-quantitative way, according to a 3-tiered scoring system in absent, focal and substantial. Results: Among 524 patients, any positive LVSI was found in 57 patients (10.9%) with focal LVSI (n=35, 6.7%) and substantial LVSI (n=2…

Oncologymedicine.medical_specialtyMultivariate analysisLymph node metastasisEndometrial Cancer03 medical and health sciences0302 clinical medicineText miningInternal medicineMedicineHumansRisk factorStage (cooking)Neoplasm MetastasisLetter to the EditorUnivariate analysis030219 obstetrics & reproductive medicineEndometrial Cancer; Neoplasm Metastasis; Prognostic FactorsEndometrial Cancer Neoplasm Metastasis Prognostic Factorsbusiness.industryPrognostic FactorsEndometrial cancerHazard ratioCancerObstetrics and GynecologyGeneral Medicinemedicine.diseasePrognosisLymphovascularEndometrial NeoplasmsSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionFemaleLymphNeoplasm Recurrence LocalbusinessCarcinoma EndometrioidJournal of gynecologic oncology
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

2020

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional surviva…

macro-vascular portal vein invasionMaleCarcinoma HepatocellularAntineoplastic Agentsextra hepatic disease and BCLCsurvivalNLRAntineoplastic AgentCohort Studiesalpha-fetoproteinHumansLymphocyte CountSurvivorsprognostic factorAgedLiver NeoplasmsMiddle AgedSorafenibProgression-Free SurvivalItalyLiver Neoplasmalpha-fetoprotein; extra hepatic disease and BCLC; hepatitis C; macro-vascular portal vein invasion; NLR; prognostic factor; survivalFemaleCohort Studiehepatitis CCarcinoma Hepatocellular ...Liver Neoplasms ...Human
researchProduct

Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognosti…

2023

Background: In this single center study, we retrospectively evaluated the calculated hemorheological profile in patients with a new diagnosis of multiple myeloma, with the aim to evaluate possible relationships with some prognostic predictors, such as ISS, albumin levels, beta2-microglobulin, red cell distribution width, and bone marrow plasma cell infiltration. Methods: In a cohort of 190 patients, we examined the calculated blood viscosity using the de Simone formula, and the albumin/fibrinogen ratio as a surrogate of erythrocyte aggregation, and then we related these parameters to prognostic factors, using the Kruskal–Wallis and the Mann–Whitney tests, respectively. Results: From our ana…

multiple myelomahemorheological patternmultiple myeloma; hemorheological pattern; calculated blood viscosity; albumin/fibrinogen ratio; prognostic factorsalbumin/fibrinogen ratioMedicine (miscellaneous)prognostic factors.calculated blood viscosityGeneral Biochemistry Genetics and Molecular BiologyBiomedicines; Volume 11; Issue 3; Pages: 964
researchProduct

ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER S…

2012

multiple myeoloma lymphocite count prognostic factorsSettore MED/15 - Malattie Del Sangue
researchProduct

Prognostic Factors in Staged Bilateral Total Knee Arthroplasty—A Retrospective Case Series Analysis

2023

Background: Bilateral osteoarthritis of the knee is an indication for a bilateral total knee replacement (TKR) procedure. The goal of our study was to assess the sizes of the implants used during the first and second stages of TKR procedures in order to compare their size and identify the prognostic factors for the second procedure. Methods: We evaluated 44 patients who underwent staged bilateral TKR procedures. We assess the following prognostic factors from the first and second surgery: duration of anesthesia, femoral component size, tibial component size, duration of hospital stay, tibial polyethylene insert size, and the number of complications. Results: All assessed prognostic factors …

total knee replacement; two-stage; prognostic factors; bilateral; predictive factorsGeneral MedicineJournal of Clinical Medicine; Volume 12; Issue 10; Pages: 3547
researchProduct